首页 | 本学科首页   官方微博 | 高级检索  
     

银杏内酯B抑制非酒精性脂肪性肝病大鼠肝脏极低密度脂蛋白输出
引用本文:武俊紫,赵茜,罗德霞,范晓明,马琼,石安华. 银杏内酯B抑制非酒精性脂肪性肝病大鼠肝脏极低密度脂蛋白输出[J]. 中国病理生理杂志, 2021, 0(2): 300-305
作者姓名:武俊紫  赵茜  罗德霞  范晓明  马琼  石安华
作者单位:云南中医药大学基础医学院;云南省高校中医证候微观辨证重点实验室;桂林医学院广西系统医学重点实验室
基金项目:国家自然科学基金项目(No.81760818);云南省科学技术厅-中医联合专项面上项目[No.2019FF002(-041),No.2019FF02(-055)]。
摘    要:目的:探讨银杏内酯B对高脂高糖饮食诱导的非酒精性脂肪性肝病大鼠肝脏极低密度脂蛋白(VLDL)输出的影响.方法:72只SD大鼠适应性喂养10 d后按照随机数字表法分为正常对照(CON)组、模型(MOD)组、阳性药物辛伐他汀(SIM)组及银杏内酯B低、中和高剂量治疗组,每组12只.除对照组外,大鼠采用高脂高糖饮食喂养12周...

关 键 词:银杏内酯B  非酒精性脂肪性肝病  极低密度脂蛋白  载脂蛋白B-100  微粒体甘油三酯转运蛋白

Ginkgolide B inhibits very-low-density lipoprotein output in liver of rats with non-alcoholic fatty liver disease
WU Jun-zi,ZHAO Xi,LUO De-xia,FAN Xiao-ming,Ma Qiong,SHI An-hua. Ginkgolide B inhibits very-low-density lipoprotein output in liver of rats with non-alcoholic fatty liver disease[J]. Chinese Journal of Pathophysiology, 2021, 0(2): 300-305
Authors:WU Jun-zi  ZHAO Xi  LUO De-xia  FAN Xiao-ming  Ma Qiong  SHI An-hua
Affiliation:(School of Basic Medicine,Yunnan University of Chinese Medicine,Kunming 650504,China;Laboratory of Microcosmic Syndrome Differentiation,Education Department of Yunnan,Kunming 650500,China;Guangxi Key Laboratory of Sys-tematic Medicine,Guilin Medical College,Guilin 541100,China)
Abstract:AIM:To study the effect of ginkgolide B on the output of very low-density lipoprotein(VLDL)in rats with non-alcoholic fatty liver disease induced by a high-fat and high-sugar diet.METHODS:After 10 d of adaptive feeding,72 SD rats were randomly divided into normal control(CON)group,model(MOD)group,positive drug simvastatin(SIM)group,and low-,medium-and high-dose ginkgolide B treatment(GB-L,GB-M and GB-H)groups via random number table method(n=10).After all rats except control rats were received a high-fat and high-sugar diet for 12 weeks,2 animals were randomly selected to test whether the modeling was successful built or not from each group.The rats in CON group and MOD group were treated with 1 mL·kg?1·d?1 saline,the rats in SIM group were treated with 2 mg·kg?1·d?1 simvastatin,and the rats in the 3 doses of ginkgolide B groups were treated with ginkgolide B at 0.5,1.0 and 2.0 mg·kg?1·d?1,respectively.After 4 weeks,the blood was collected for liver function and lipid(VLDL and LDL)determination,and the liver was collected for liver histopathological observation,hepatic lipid(VLDL and LDL)testing and detection of microsomal triglyceride transfer protein(MTP)and apolipoprotein B-100(ApoB-100)protein expression by immunofluorescence and Western blot.RESULTS:Compared with CON group,alanine aminotransferase(ALT),aspartate aminotransferase(AST),VLDL and LDL in serum,VLDL and LDL in liver tissues were significantly increased in MOD group(P<0.05).Compared with MOD group,the above indicators were significantly reduced in SIM group and 3 ginkgolide B groups(P<0.05).The liver histopathological observation showed that the cells in CON group were neatly arranged,uniform in size,and the nuclei were basically distributed in the center of the cells.The slices in MOD group were filled with a large number of fat vacuoles,and the nuclei were squeezed and distributed close to the cell membrane.The cell morphological changes in each treatment group were significantly better than those in MOD group.Compared with CON group,the expression levels of MTP and ApoB-100 in MOD group were significantly increased(P<0.05),while both SIM and ginkgolide B significantly reduced the expression of MTP and ApoB-100(P<0.05).CONCLUSION:Ginkgolide B reduces the VLDL output of non-alcoholic fatty liver disease rats by regulating MTP and ApoB-100,thereby protecting the liver.
Keywords:Ginkgolide B  Non-alcoholic fatty liver disease  Very low density lipoprotein  Apolipoprotein B-100  Microsomal triglyceride transper protein
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号